Benzinga | Dec 15, 2021 09:04AM EST

Quoin Pharma Reports Exclusive Distribution Deal With Orpharm For QRX003 For Netherton Syndrome, No Terms Disclosed

Orpharm Gains Exclusive Rights to Commercialize QRX003 in Russia and CIS

ASHBURN, Va., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) (the "Company" or "Quoin"), a specialty pharmaceutical company focused on rare and orphan diseases, today announced that its wholly-owned subsidiary, Quoin Pharmaceuticals, Inc., has entered into an exclusive Distribution Agreement with Orpharm LLC ("Orpharm") for QRX003, the Company's investigational treatment for Netherton Syndrome, a rare and devastating genetic disease, for which there is currently no available treatment or cure.

Under the terms of the agreement, Orpharm gains exclusive rights to commercialize QRX003 in Russia and CIS, and Quoin is obligated to supply the product to Orpharm, upon the receipt of regulatory approval.

Dr. Michael Myers, Chief Executive Officer of Quoin, commented, "This distribution agreement with Orpharm is our third partnership agreement for QRX003 in less than two months and underscores Quoin's commitment to make our products available to as many patients as possible upon the receipt of regulatory approval. We are very pleased that Orpharm has become our partner for Russia and CIS and we look forward to working with them to bring this potential treatment to a very underserved patient population."

"We are excited to partner with Quoin. QRX003 will be a much needed solution to patients suffering from Netherton syndrome in our region. We are committed to supporting Quoin and leveraging our relationships with dermatologists and the broader rare disease community," states Pavel Shestiperov, M.D., CEO of Orpharm.